BioNet at MSS2026
Representing BioNet, Mukesh Chauhan, Director Production, will present"Evolution of Vaccine Technologies: From Recombinant Vaccines to pDNA and mRNA Platforms" on 15 September 2026 at 3:15 – 3:40 PM.
contact: [email protected]
4
mdpi.com/2076-393X/14/9/736 An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond
9
BioNet will be heading to Bologna, Italy (June 1–5) for the 44th Annual Meeting of the European Society for Paediatric Infectious Diseases.
18
BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing
Read more: bionet.one
23
Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy
pmc.ncbi.nlm.nih.gov/article…
At BioNet, we are committed to bridging these immunization gaps through innovative vaccine development — targeting respiratory diseases like whooping cough — and exploring mRNA platforms to better prepare for tomorrow’s public health needs.
BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation
bionet.one/bionet-wins-barda…
22
🎉 🎄 Holiday Wishes and Season’s Greetings from BioNet
May this holiday season bring you moments of joy and a healthier New Year filled with growth and success. Thank you for making this year special and for being part of our mission towards a healthier and safer world.
20









